New drug from lizard's saliva
[[Image:fda.jpg|125px|right|]]
{{date|April 30, 2005}}

A chemical part of the saliva of a poisonous lizard, the [[:w:Gila monster|Gila monster]], has become an integral partner in the control of Type 2 [[:w:diabetes|diabetes]]. The U.S. [[:w:Food and Drug Administration|Food and Drug Administration]] has approved its use for people who have not achieved adequate control of their diabetes with oral medications.

Byetta, or exenatide, is produced by Amylin Pharmaceuticals. It is injected before eating morning and evening meals as part of a combination treatment with oral drugs. The FDA said it could be approved as a stand-alone treatment if the drug companies can support such use with data.

[[:w:Eli Lilly & Co|Eli Lilly & Co]]. was the development partner in creation of the drug.

"With Byetta's demonstrated effects on blood sugar and its safety profile, physicians and patients now have a new approach to fight the growing diabetes epidemic," said Sidney Taurel, CEO of Lilly.
== Sources ==
*{{source|url=http://www.nytimes.com/2005/04/30/business/30drug.html|title=Lizard-Derived Diabetes Drug Is Approved by the F.D.A.|author=Andrew Pollack |pub=The New York Times-Business|date=April 30, 2005}}
*{{source|url=http://www.marketwatch.com/news/story.asp?guid={AC7C0389-F90E-45F4-8436-462C25BD789A}&symb=AMLN&sid=8365&siteid=NYT&dist=NYT&osymb=AMLN |title= Amylin falls after drug approval - Biotechnology - Pharmaceuticals - Company Announcements|author=Val Brickates Kennedy |pub= MarketWatch |date=April 30, 2005}}
*[http://www.healthtalk.ca/diabetes_drug_043005_90392.php New Diabetes Drug Made From Lizard Saliva] ''Healthtalk Canada'' April 30, 2005

{{publish}}
{{archive}}

[[Category:Health]]
[[Category:Biotechnology]]
[[Category:North America]]
[[Category:United States]]
[[Category:Food and Drug Administration]]
A chemical part of the saliva of a poisonous lizard, the Gila monster, has become an integral partner in the control of Type 2 diabetes. The U.S. Food and Drug Administration has approved its use for people who have not achieved adequate control of their diabetes with oral medications.

Byetta, or exenatide, is produced by Amylin Pharmaceuticals. It is injected before eating morning and evening meals as part of a combination treatment with oral drugs. The FDA said it could be approved as a stand-alone treatment if the drug companies can support such use with data.

Eli Lilly & Co. was the development partner in creation of the drug.

"With Byetta's demonstrated effects on blood sugar and its safety profile, physicians and patients now have a new approach to fight the growing diabetes epidemic," said Sidney Taurel, CEO of Lilly.
Health Biotechnology North America United States Food and Drug Administration